<DOC>
	<DOC>NCT01405508</DOC>
	<brief_summary>This is a multicenter, open-label, 4-arm, randomized, parallel-group study to evaluate safety and tolerability of Brivaracetam Intravenous (BRV iv) as adjunctive treatment for adults with epilepsy according to an initiation or a conversion scheme, during repeated dosing (100 mg/administration twice daily for 4.5 days).</brief_summary>
	<brief_title>Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy</brief_title>
	<detailed_description>Eligible subjects will be randomized in a 1:1:1:1 ratio to the 4 treatment arms</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>An Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written Informed Consent form signed and dated by the subject or by parent(s) or legal representative Subjects from 16 to 70 years Subjects with a body weight of &gt;/= 40 kg Female subjects without childbearing potential or female subjects with childbearing potential if they use a medically accepted contraceptive method Subject/legal representative considered as reliable and capable of adhering to the protocol Subjects with wellcharacterized focal or generalized epilepsy or epileptic syndrome Subjects with a history of partialonset seizures whether or not secondarily generalized or primary generalized seizures Subjects being uncontrolled while treated with 1 to 2 permitted concomitant antiepileptic drugs (AEDs) Permitted concomitant antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) being stable and at optimal dosage for the subject from at least 1 month before Visit 1 and expected to be kept stable during the RunIn and Evaluation Periods Mentally impaired subjects unable to understand the study purpose History or presence of status epilepticus during 1 year preceding Visit 1 or Baseline Subjects on felbamate with less than 18 months continuous exposure before Visit 1 Subjects currently on vigabatrin Subject taking any drug with possible relevant central nervous system effects except is stable from at least 1 month before Visit 1 and expected to be kept stable during the trial Subjects taking any drug that may significantly influence the metabolism of Brivaracetam (BRV) except if the dose has been kept stable at least 1 month before Visit 1, and is expected to be kept stable during the trial History of cerebrovascular accident in the last 6 months Subjects suffering from severe cardiovascular disease or peripheral vascular disease Presence of any sign suggesting rapidly progressing brain disorder or brain tumor Any clinical conditions which impair reliable participation in the study or necessitate the use of medication not allowed by protocol Presence of a terminal illness Presence of a serious infection Subjects with a history of sever adverse hematologic reaction to any drug Subjects suffering from severe disturbance of hemostasis Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gammaglutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range Subjects having clinically significant deviations from reference range values for laboratory parameters: creatinine clearance calculated &lt; 50 ml / min, platelets &lt; 100,000 / µL, or neutrophil cells &lt; 1,800 / µL Clinically significant electrocardiogram (ECG) abnormalities according to the Investigator History of suicide attempt In the Investigator's medical judgment, any current suicidal ideation or other serious psychiatric disorders requiring of having required hospitalization or medication Known allergic reaction or intolerance to pyrrolidone derivatives and / or investigational product excipients Known multiple drug allergies or severe drug allergy Pregnant or lactating women Known alcohol or drug addiction or abuse within the last 2 years Subject institutionalized under judicial decision Problems of venous accessibility Subject taking part in another clinical / pharmacological study in the month preceding enrollment (Visit 1) Investigators, coinvestigators, their spouses or children, or any study collaborators Subjects previously treated with Brivaracetam (BRV) Subject previously screened within this study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>N01258</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>IV</keyword>
	<keyword>intravenous</keyword>
</DOC>